MedTrace Logo

Effect of SGLT2 Inhibitors on Anemic CKD Patients

NCT07334145 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-01-14

No results posted yet for this study

Summary

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Conditions

  • Anemia in CKD Patients

Interventions

DRUG

SGLT2 inhibitor

prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Romany Naguib Mikhaeil, master · Sohag University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-07-01
Completion
2026-09-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07334145 on ClinicalTrials.gov